INS and type 2 diabetes mellitus: In an HFD/low-dose STZ-induced T2DM animal model, the oral administration of sinapic acid (25 mg/kg/day for 30 days) significantly improved glycemic control, as indicated by reductions in fasting blood glucose and glycosylated hemoglobin levels, along with increased plasma insulin levels [145].